Hidradenitis Suppurativa Market: Latest Study by DelveInsight Forecasts Remarkable Growth During the Forecast Period (2023-32) | InflaRx, Novartis, UCB, Eli Lilly, Janssen, AbbVie, Pfizer, Amgen

Hidradenitis Suppurativa Market: Latest Study by DelveInsight Forecasts Remarkable Growth During the Forecast Period (2023-32) | InflaRx, Novartis, UCB, Eli Lilly, Janssen, AbbVie, Pfizer, Amgen
Delveinsight Business Research LLP
Hidradenitis Suppurativa Market size in the 7MM is expected to increase at a CAGR of 13.5% owing to the increasing awareness of the disease and the launch of the emerging therapy. Hidradenitis Suppurativa Companies like Novartis, UCB Biopharma, ACELYRIN, AbbVie, Incyte, Moonlake Therapeutics, and others are evaluating their lead candidates in different stages of clinical development.

DelveInsight’s “Hidradenitis Suppurativa Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hidradenitis Suppurativa market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Hidradenitis Suppurativa drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Hidradenitis Suppurativa treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Hidradenitis Suppurativa: An Overview

Hidradenitis Suppurativa (HS) is a complex dermatological disease characterized by recurrent painful nodules and suppuration in areas such as the axilla and groin. It is also known as Acne inversa and there is no biological or pathological test to facilitate diagnosis, it can be defined by its clinical features and its chronicity.

The exact cause of hidradenitis suppurativa is unclear, but the condition probably results from a combination of genetic and environmental factors. Lumps develop as a result of blocked hair follicles. It is more common in women than in men and in obese and smokers, Hidradenitis Suppurativa is likely to worsen the symptoms

The symptoms of hidradenitis suppurativa range from mild to severe. It causes a mixture of boil-like lumps, blackheads, cysts, scarring, and channels in the skin that leak pus. Scoring systems for the assessment of Hidradenitis Suppurativa severity include Hurley staging, Physician’s Global Assessment (PGA), the modified Sartorius score (MSS), and Hidradenitis Suppurativa Severity Index (HSSI). Patients with Hidradenitis Suppurativa need wound care not only after surgery, to address Hidradenitis Suppurativa scarring and tunneling from sinus tracts; they also need ongoing wound care for lesions that might be draining.

More than dressings may be necessary for Hidradenitis Suppurativa patients who have wounds from surgery to remove scarring and tunnels. To ensure the patient heals as rapidly as possible, dermatologists and others should take into account advanced wound therapy, such as advanced wound dressings for delayed wounds, cell-based therapy, growth factors, or negative pressure wound therapy.

Hidradenitis Suppurativa Market Key Facts

  • The total market size of Hidradenitis Suppurativa in the United States was approximately USD 600 million in 2019 and is projected to increase during the forecast period (2023–2032).

  • Among EU4 countries, Germany accounted for the maximum market size in 2022, while Spain occupied the bottom of the ladder.

  • In 2032, among all the emerging therapies, BIMZELX is expected to generate the highest revenue in the 7MM.

  • In 2019, the total prevalent cases of Hidradenitis Suppurativa were approximately 2.8 million cases in the US, which is expected to grow during the study period, i.e., 2019–2032.

  • Among EU4 and the UK, Germany accounted for the highest number of Hidradenitis Suppurativa prevalent cases, while Spain accounted for the least prevalent cases.

  • In the US and EU, Hidradenitis Suppurativa is more common in females than males, but in Japan, it is the opposite, as, in Japan, males are more commonly affected than females.

  • The highest proportion of Hidradenitis Suppurativa prevalent pool was observed in the 30–39 years age group among all the countries.

Hidradenitis Suppurativa Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Hidradenitis Suppurativa pipeline therapies. It also thoroughly assesses the Hidradenitis Suppurativa market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Hidradenitis Suppurativa drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Hidradenitis Suppurativa Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Hidradenitis Suppurativa epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Hidradenitis Suppurativa epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Hidradenitis Suppurativa Epidemiology, Segmented as –

  • Total Prevalent Pool of Hidradenitis Suppurativa

  • Gender-specific Prevalent Pool of Hidradenitis Suppurativa 

  • Age-specific Prevalent Pool of Hidradenitis Suppurativa 

  • Stage-specific Prevalent Pool of Hidradenitis Suppurativa

  • Diagnosed Pool of Hidradenitis Suppurativa 

  • Treated Prevalent Pool of Hidradenitis Suppurativa 

Hidradenitis Suppurativa Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Hidradenitis Suppurativa market or expected to be launched during the study period. The analysis covers the Hidradenitis Suppurativa market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Hidradenitis Suppurativa drugs based on their sale and market share.

The report also covers the Hidradenitis Suppurativa pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Hidradenitis Suppurativa companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Hidradenitis Suppurativa Market Will Evolve and Grow by 2032 @ 


Hidradenitis Suppurativa Therapeutics Analysis

Currently, treatment and management usually requires a combination of lifestyle changes, medical therapy, laser or surgical intervention, dressings, and considerable psychological support. There are a number of pharmacological treatment options, including topical and systemic antibiotics, corticosteroids, anti-androgen therapy, systemic retinoids, and immunosuppressive agents including biologics. 

Several major pharma and biotech companies are developing therapies for Hidradenitis Suppurativa. Currently, InflaRx is leading the therapeutics market with its Hidradenitis Suppurativa drug candidates in the most advanced stage of clinical development.

Hidradenitis Suppurativa Companies Actively Working in the Therapeutics Market Include

  •  InflaRx

  • Novartis

  • UCB

  • ChemoCentryx

  • Eli Lilly and Company

  • Janssen Biotech

  • AbbVie

  • Pfizer

  • Amgen

  • Incyte Corporation

  • CSL Behring

  • Kymera Therapeutics

  • Lytix Biopharma

  • Aclaris Therapeutics

  • Boehringer Ingelheim

  • Azora Therapeutics

And Many Others

Emerging and Marketed Hidradenitis Suppurativa Therapies Covered in the Report Include:

  • Vilobelimab: InflaRx

  • Secukinumab: Novartis

  • Avacopan: ChemoCentryx

  • Imsidolimab: AnaptysBio

  • Spesolimab: Boehringer Ingelheim

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Hidradenitis Suppurativa Competitive Intelligence Analysis

4. Hidradenitis Suppurativa Market Overview at a Glance

5. Hidradenitis Suppurativa Disease Background and Overview

6. Hidradenitis Suppurativa Patient Journey

7. Hidradenitis Suppurativa Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Hidradenitis Suppurativa Treatment Algorithm, Current Treatment, and Medical Practices

9. Hidradenitis Suppurativa Unmet Needs

10. Key Endpoints of Hidradenitis Suppurativa Treatment

11. Hidradenitis Suppurativa Marketed Therapies

12. Hidradenitis Suppurativa Emerging Drugs and Latest Therapeutic Advances

13. Hidradenitis Suppurativa Seven Major Market Analysis

14. Attribute Analysis

15. Hidradenitis Suppurativa Market Outlook (In US, EU5, and Japan)

16. Hidradenitis Suppurativa Companies Active in the Market

17. Hidradenitis Suppurativa Access and Reimbursement Overview

18. KOL Views on the Hidradenitis Suppurativa Market

19. Hidradenitis Suppurativa Market Drivers

20. Hidradenitis Suppurativa Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @




About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Papilloma Market

“Papilloma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Papilloma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Papilloma market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research